Krystal Biotech (KRYS) Set to Announce Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS - Get Free Report) will release its earnings data before the market opens on Monday, May 6th. Analysts expect Krystal Biotech to post earnings of $0.28 per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same period in the prior year, the firm earned ($1.25) EPS. On average, analysts expect Krystal Biotech to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Krystal Biotech Trading Up 0.7 %

Krystal Biotech stock traded up $1.11 during mid-day trading on Monday, reaching $157.99. The company's stock had a trading volume of 196,281 shares, compared to its average volume of 361,733. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of 1,974.88 and a beta of 0.85. The business has a 50 day moving average price of $164.33 and a 200-day moving average price of $131.82. Krystal Biotech has a twelve month low of $82.09 and a twelve month high of $189.97.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Guggenheim lifted their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. HC Wainwright reissued a "buy" rating and set a $200.00 price target on shares of Krystal Biotech in a report on Monday, April 22nd. William Blair reissued an "outperform" rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Stifel Nicolaus reissued a "buy" rating and set a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech presently has a consensus rating of "Buy" and a consensus target price of $171.00.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CAO Kathryn Romano sold 8,087 shares of the business's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares of the company's stock, valued at approximately $1,719,041.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,087 shares of company stock worth $6,210,591. Company insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).